To embed, copy and paste the code into your website or blog:
Hospitals in the Washington, D.C., area got generally lackluster ratings for quality and safety of health care in the latest reviews by federal and independent groups. Two well-known D.C. hospitals got one star, the lowest ranking, in a federal survey, while a nonprofit rater gave another D.C. hospital a flunking grade of F.
The reviewers, due to the coronavirus, suspended their 2020 ratings, so the new measurements were the first in many months and they showed, to a degree, how institutions held up during the pandemic. The rankings also underscored the urgency of local officials’ announced plans to revamp hospital care, including helping to fund two new facilities.
From crazy sock day to aloha day, she’s finding ways to inspire and lift her patients and nursing colleagues.
Watkins is in charge of an all-COVID-19 unit and has picked up extra shifts on the weekends. She said she’s been there for loved ones who’ve gotten the news of a family member dying of COVID-19.
“To sit in those rooms with those patients while they’re grieving has been very challenging, very draining. But it’s what we do every day, and they need somebody there,” Watkins said.
She also started a program called Code Lavender. If a nurse is having a tough time, they get a special goody bag filled with snacks and a note letting them know they are not alone.
E-Mail
WASHINGTON - The Society for Cardiovascular Angiography and Interventions (SCAI) presented its Master Interventionalists of SCAI (MSCAI) designations during the SCAI 2020 Scientific Sessions Virtual Conference MSCAI recognition ceremony.
The MSCAI designation is awarded to individuals who have demonstrated excellence in invasive/interventional cardiology over the course of their career and for their commitment to the highest levels of clinical care, innovation, publication, and teaching.
This year s MSCAI designations were awarded to the following group of outstanding interventionalists:
Ian C. Gilchrist, MD, MSCAI
Dr. Ian C. Gilchrist is a professor of medicine for Penn State University s College of Medicine at the Hershey Medical Center in Hershey, PA. Dr. Gilchrist graduated from Dartmouth College in Hanover, NH and then obtained his medical degree from Columbia University. He received his residency and cardiology fellowship training at the St. Luke s/Roosevelt Hosp
May 03, 2021
Long-term dual antiplatelet therapy (DAPT) reduces ischemic events without a trade-off in bleeding compared with shorter durations among ACS patients who undergo PCI, according to new registry data from China.
The findings, released at the virtual Society for Cardiovascular Angiography and Interventions (SCAI) 2021 meeting, are slightly out of step with the TWILIGHT ACS substudy, which indicated a shorter duration of DAPT followed by ticagrelor monotherapy lowers bleeding risk in these patients without increasing ischemic events. In the Chinese registry, DAPT primarily consisted of clopidogrel and aspirin.
“To the best of our knowledge, this is the first report investigating the feasibility and safety of long-term DAPT for high-risk ‘TWILIGHT-like’ patients with ACS treated with DES,” Hao-Yu Wang, MD (Fuwai Hospital, Beijing, China), said in his presentation. “These results suggested that prolonged DAPT in ACS patients who present with a particularly higher